Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2004

View Archived Issues

Series C financing to fund development of Chimerix smallpox drug

ViroPharma receives antitrust clearance for U.S. acquisition of Vancocin

Solvay and Novozymes to develop new enzyme replacement products

Peplin to raise funds to support phase II studies of PEP-005 Topical

Approval for new formulation of TriCor

IDM, Walter Reed Army Institute of Research sign cancer vaccine agreement

Bristol-Myers Squibb and Medarex collaborate on MDX-010 development

BCX-4208 enters clinical development for psoriasis

Preliminary findings for uterine fibroid study of Progenta

Panacos amends merger agreement with V.I. Technologies

Nastech initiates feasibility studies in type 2 diabetes and Alzheimer's

Advexin plus chemotherapy effective against head and neck cancer cells

Aventis terminates Genasense agreements with Genta

5-HT6 receptor agonist WAY-466 shows good in vitro/in vivo pharmacological profile

RMG-10029: a new modified quinolone with anxiolytic activity

Selective muscarinic M1 receptor agonist improves cognition in rodents

Ginseng derivative shows SERM activity

Potent inhibition of HIV entry by CCR5 mAb

First-in-class antibacterial ECO-00501 active against Gram-positive bacteria

Senju researchers describe novel antibacterial agents

Novel neutral endopeptidase inhibitors reported by Pfizer

CETP inhibitors described by Pfizer researchers

Pharmacia claims combined therapy against tumors

Ranbaxy patent claims metformin tablets for the treatment of diabetes

Fasudil inhibits tracheal contraction induced by neostigmine in rats

Anecortave acetate shows efficacy in maintaining visual acuity of patients with wet AMD

New clinical data on the efficacy of SnET2 photodynamic therapy in AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...